Cargando…

Bridging the In Vitro to In Vivo gap: Using the Chick Embryo Model to Accelerate Nanoparticle Validation and Qualification for In Vivo studies

[Image: see text] We postulate that nanoparticles (NPs) for use in therapeutic applications have largely not realized their clinical potential due to an overall inability to use in vitro results to predict NP performance in vivo. The avian embryo and associated chorioallantoic membrane (CAM) has eme...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, Kimberly S., Brinker, C. Jeffrey, Leong, Hon Sing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799072/
https://www.ncbi.nlm.nih.gov/pubmed/36453753
http://dx.doi.org/10.1021/acsnano.2c03990
_version_ 1785145824713375744
author Butler, Kimberly S.
Brinker, C. Jeffrey
Leong, Hon Sing
author_facet Butler, Kimberly S.
Brinker, C. Jeffrey
Leong, Hon Sing
author_sort Butler, Kimberly S.
collection PubMed
description [Image: see text] We postulate that nanoparticles (NPs) for use in therapeutic applications have largely not realized their clinical potential due to an overall inability to use in vitro results to predict NP performance in vivo. The avian embryo and associated chorioallantoic membrane (CAM) has emerged as an in vivo preclinical model that bridges the gap between in vitro and in vivo, enabling rapid screening of NP behavior under physiologically relevant conditions and providing a rapid, accessible, economical, and more ethical means of qualifying nanoparticles for in vivo use. The CAM is highly vascularized and mimics the diverging/converging vasculature of the liver, spleen, and lungs that serve as nanoparticle traps. Intravital imaging of fluorescently labeled NPs injected into the CAM vasculature enables immediate assessment and quantification of nano-bio interactions at the individual NP scale in any tissue of interest that is perfused with a microvasculature. In this review, we highlight how utilization of the avian embryo and its CAM as a preclinical model can be used to understand NP stability in blood and tissues, extravasation, biocompatibility, and NP distribution over time, thereby serving to identify a subset of NPs with the requisite stability and performance to introduce into rodent models and enabling the development of structure–property relationships and NP optimization without the sacrifice of large populations of mice or other rodents. We then review how the chicken embryo and CAM model systems have been used to accelerate the development of NP delivery and imaging agents by allowing direct visualization of targeted (active) and nontargeted (passive) NP binding, internalization, and cargo delivery to individual cells (of relevance for the treatment of leukemia and metastatic cancer) and cellular ensembles (e.g., cancer xenografts of interest for treatment or imaging of cancer tumors). We conclude by showcasing emerging techniques for the utilization of the CAM in future nano-bio studies.
format Online
Article
Text
id pubmed-9799072
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-97990722023-12-01 Bridging the In Vitro to In Vivo gap: Using the Chick Embryo Model to Accelerate Nanoparticle Validation and Qualification for In Vivo studies Butler, Kimberly S. Brinker, C. Jeffrey Leong, Hon Sing ACS Nano [Image: see text] We postulate that nanoparticles (NPs) for use in therapeutic applications have largely not realized their clinical potential due to an overall inability to use in vitro results to predict NP performance in vivo. The avian embryo and associated chorioallantoic membrane (CAM) has emerged as an in vivo preclinical model that bridges the gap between in vitro and in vivo, enabling rapid screening of NP behavior under physiologically relevant conditions and providing a rapid, accessible, economical, and more ethical means of qualifying nanoparticles for in vivo use. The CAM is highly vascularized and mimics the diverging/converging vasculature of the liver, spleen, and lungs that serve as nanoparticle traps. Intravital imaging of fluorescently labeled NPs injected into the CAM vasculature enables immediate assessment and quantification of nano-bio interactions at the individual NP scale in any tissue of interest that is perfused with a microvasculature. In this review, we highlight how utilization of the avian embryo and its CAM as a preclinical model can be used to understand NP stability in blood and tissues, extravasation, biocompatibility, and NP distribution over time, thereby serving to identify a subset of NPs with the requisite stability and performance to introduce into rodent models and enabling the development of structure–property relationships and NP optimization without the sacrifice of large populations of mice or other rodents. We then review how the chicken embryo and CAM model systems have been used to accelerate the development of NP delivery and imaging agents by allowing direct visualization of targeted (active) and nontargeted (passive) NP binding, internalization, and cargo delivery to individual cells (of relevance for the treatment of leukemia and metastatic cancer) and cellular ensembles (e.g., cancer xenografts of interest for treatment or imaging of cancer tumors). We conclude by showcasing emerging techniques for the utilization of the CAM in future nano-bio studies. American Chemical Society 2022-12-01 2022-12-27 /pmc/articles/PMC9799072/ /pubmed/36453753 http://dx.doi.org/10.1021/acsnano.2c03990 Text en © 2022 The Authors. Published by American Chemical Society https://pubs.acs.org/page/policy/termsofuse.htmlMade available for a limited time for personal research and study only License (https://pubs.acs.org/page/policy/termsofuse.html) .
spellingShingle Butler, Kimberly S.
Brinker, C. Jeffrey
Leong, Hon Sing
Bridging the In Vitro to In Vivo gap: Using the Chick Embryo Model to Accelerate Nanoparticle Validation and Qualification for In Vivo studies
title Bridging the In Vitro to In Vivo gap: Using the Chick Embryo Model to Accelerate Nanoparticle Validation and Qualification for In Vivo studies
title_full Bridging the In Vitro to In Vivo gap: Using the Chick Embryo Model to Accelerate Nanoparticle Validation and Qualification for In Vivo studies
title_fullStr Bridging the In Vitro to In Vivo gap: Using the Chick Embryo Model to Accelerate Nanoparticle Validation and Qualification for In Vivo studies
title_full_unstemmed Bridging the In Vitro to In Vivo gap: Using the Chick Embryo Model to Accelerate Nanoparticle Validation and Qualification for In Vivo studies
title_short Bridging the In Vitro to In Vivo gap: Using the Chick Embryo Model to Accelerate Nanoparticle Validation and Qualification for In Vivo studies
title_sort bridging the in vitro to in vivo gap: using the chick embryo model to accelerate nanoparticle validation and qualification for in vivo studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799072/
https://www.ncbi.nlm.nih.gov/pubmed/36453753
http://dx.doi.org/10.1021/acsnano.2c03990
work_keys_str_mv AT butlerkimberlys bridgingtheinvitrotoinvivogapusingthechickembryomodeltoacceleratenanoparticlevalidationandqualificationforinvivostudies
AT brinkercjeffrey bridgingtheinvitrotoinvivogapusingthechickembryomodeltoacceleratenanoparticlevalidationandqualificationforinvivostudies
AT leonghonsing bridgingtheinvitrotoinvivogapusingthechickembryomodeltoacceleratenanoparticlevalidationandqualificationforinvivostudies